Clinical Trials Logo

Cardio-Renal Syndrome clinical trials

View clinical trials related to Cardio-Renal Syndrome.

Filter by:

NCT ID: NCT03628443 Recruiting - Heart Failure Clinical Trials

Cardiorenal Risk Stratification Pilot Study

CRiSPS
Start date: July 19, 2018
Phase:
Study type: Observational

This is prospective cohort study with the purpose of improving our understanding of morbidity and mortality risk in patients with heart failure and chronic kidney disease.

NCT ID: NCT03176862 Recruiting - Clinical trials for Chronic Kidney Diseases

Left Ventricular Fibrosis in Chronic Kidney Disease

FibroCKD
Start date: September 2015
Phase: N/A
Study type: Observational

This study aims to understand the onset an functional consequences of left ventricular interstitial fibrosis in patients with chronic kidney disease (stage 2 to 5), as well as assess whether transplantation results in a regression of cardiac fibrosis.Thus all patients will undergo: 1) a cardiac magnetic resonance imaging (MRI) scan to assess cardiac function and measure left ventricular interstitial fibrosis; 2) a cardiopulmonary stress echocardiogram to understand the functional consequences of fibrosis and rule out any underlying ischaemic heart disease; 3) a 24 hour holter monitor and electrocardiogram (ECG) to assess whether these patients are at higher risk of arrhythmia.

NCT ID: NCT02846337 Recruiting - Clinical trials for Cardio-renal Syndrome

Ultrafiltration Versus Medical Therapies in the Management of the Cardio Renal Syndrome

UF-CARE
Start date: March 31, 2017
Phase: N/A
Study type: Interventional

Type 2 cardio renal syndrome is defined by the occurrence or the exacerbation of a kidney failure induced by a chronic heart failure. Sodium overload is one of the main causes leading to the occurrence or the exacerbation of this syndrome. Some patients have a massive sodium retention on which medications are not effective enough. These patients have no further therapeutic options because of the refractory congestion and a 3-months mortality rate around 15%, frequent rehospitalization (3-months rehospitalization rate at 71%) and an excessively impaired quality of life. For those refractory heart failure with cardio renal syndrome, nephrology departments resort to non-medication sodium extraction (hemodialysis, peritoneal dialysis, isolated ultrafiltration). Between 2002 and 2008, 927 French patients would have start dialysis in this situation. In 2013, 174 patients start dialysis in 97 dialysis centers. French National Authority of Health recently published new Good Practice Guidance thereupon, strengthened by the increasing number of publications and the widespread use of this technique. There is therefore a consensus among professionals about the benefits of such a technique in those indications. However, bibliographical data are not strong enough to support a strong level of evidence. None of foresight strategies have been compared to others in a proper randomized controlled trial, and there is no clue about any suspected superiority from one strategy to another. So far, the investigators propound invasive, expensive and not validated techniques to patients with functional and vital prognosis altered. The investigators think it's essential to prove the efficacy of such an approach. They wish to quantify those techniques impact on rehospitalization, with a consideration for the potential survival impact. It seems unethical to evaluate separated techniques, taking in account that patients with severe heart failure will switch from one technique to another among their care. It is therefore crucial to validate benefits from an invasive procedure (hemodialysis, peritoneal dialysis, isolated ultrafiltration) compared to a medication-restricted care.

NCT ID: NCT02343393 Recruiting - Clinical trials for Cardio-Renal Syndrome

Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study

NICHE
Start date: January 2015
Phase: Phase 3
Study type: Interventional

This is a single-blind, randomised, clinical trial assessing the efficacy of Hydralazine and Isosorbidedinitrate combination (oral agents) in HF patients with renal dysfunction.